|1.||Vogelzang, Nicholas J: 1 article (11/2004)|
|2.||Janisch, Linda: 1 article (11/2004)|
|3.||Ratain, Mark J: 1 article (11/2004)|
|4.||Undevia, Samir D: 1 article (11/2004)|
|5.||Mani, Sridhar: 1 article (11/2004)|
|6.||Mauer, Ann M: 1 article (11/2004)|
|7.||Dionne, Craig: 1 article (09/2003)|
|8.||Strock, Christopher J: 1 article (09/2003)|
|9.||Denmeade, Samuel R: 1 article (09/2003)|
|10.||Jones-Bolin, Susan: 1 article (09/2003)|
11/01/2004 - "A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. "
11/01/2004 - "Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. "
09/01/2003 - "CEP-751 and its prodrug, CEP-2563, also inhibited tumor growth in MTC cell xenografts. "
11/01/2004 - "Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors."
09/01/1999 - "This review presents the hypothesis of the neurotrophin-trk receptors as a viable molecular target for medicinal chemical intervention in tumor biology, followed by an overview of the pre-clinical studies which culminated in the advancement of the first potent trk tyrosine kinase inhibitor CEP-2563 (KT-8391), and the orally active K-252a analog, CEP-701 (KT-5555) into clinical evaluation."
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||K 252 (K252a)
|6.||tyrosine receptor (receptor, tyrosine)
|1.||Heterologous Transplantation (Xenotransplantation)